Five-year tumor-free survival after aggressive trimodality therapy for T3N0M1b non-small cell lung cancer with synchronous solitary brain metastasis

Several recent studies have demonstrated that some patients might benefit from aggressive therapy for thoracic stage I lung cancer and synchronous solitary brain metastasis. However, the indication for the patients with advanced T-stage is still unclear. We herein present a patient with synchronous solitary brain metastasis from non-small cell lung cancer who survived without recurrence for 5 years following surgery after chemotherapy, even though the primary tumor was T3N0 thoracic stage II. Aggressive treatment for both the primary site and brain metastasis may therefore be an effective treatment for locally advanced non-small cell lung cancer patients with synchronous solitary brain metastasis.